CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update

CymaBay Therapeutics (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the quarter and fiscal year ended December 31, 2017.

As quoted in the press release:

“We had a transformational year in 2017, with significant progress across clinical, operational and financial objectives, focused on advancing our pipeline,” said Sujal Shah, President and Chief Executive Officer of CymaBay.  “Our lead candidate, seladelpar, generated positive proof-of-concept data in primary biliary cholangitis (PBC), demonstrating it has the potential to offer patients improved efficacy and better tolerability compared to current second line treatment. The out-licensing of our Phase 3 ready gout asset, arhalofenate, to Kowa Pharmaceuticals America allowed us to monetize the value of that asset for stockholders and devote our full attention to developing therapies for liver diseases.”

Click here to read the full press release.